• 1. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines

Research Briefing on 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine (CAS: 1781004-23-6): Recent Advances and Applications

2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine (CAS: 1781004-23-6) is a brominated phenethylamine derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and neuroscience research. This compound belongs to a class of psychoactive substances and has been investigated for its interactions with neurotransmitter systems, particularly serotonin and dopamine receptors. Recent studies have explored its pharmacological properties, synthetic pathways, and potential therapeutic uses, making it a subject of interest for researchers in the field of psychopharmacology and drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry investigated the synthesis and receptor binding profiles of 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine. The research team employed a multi-step synthetic route to produce the compound with high purity and yield, followed by in vitro assays to evaluate its affinity for various neurotransmitter receptors. The results indicated moderate affinity for 5-HT2A and 5-HT2C serotonin receptors, suggesting potential psychoactive effects similar to other phenethylamine derivatives. This finding has implications for the development of novel psychiatric medications and the study of serotonin-related disorders.

In the field of neuropharmacology, a recent preclinical study (2024) examined the behavioral effects of 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine in animal models. The research, published in Psychopharmacology, demonstrated that the compound produces dose-dependent effects on locomotor activity and sensory perception, with a unique profile distinct from classical psychedelics. These findings contribute to our understanding of structure-activity relationships among psychoactive phenethylamines and may inform future drug design efforts targeting specific neurotransmitter systems.

From a chemical perspective, advances in the synthetic methodology of 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine have been reported in several recent publications. A 2023 paper in Organic Process Research & Development described an optimized synthetic route that improves yield and reduces byproducts, making the compound more accessible for research purposes. The improved synthesis involves selective bromination of dimethoxyphenyl precursors followed by reductive amination, with careful control of reaction conditions to prevent degradation of the sensitive bromo substituent.

Regulatory and safety aspects of 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine have also been addressed in recent literature. A 2024 review in Drug Testing and Analysis highlighted the compound's emergence in forensic casework and discussed analytical methods for its detection in biological samples. The review emphasized the need for continued research into its pharmacokinetics and potential health effects, as the compound's psychoactive properties and legal status remain areas of active investigation in many jurisdictions.

Looking forward, researchers are exploring potential therapeutic applications of 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine derivatives. Preliminary studies suggest that structural modifications of the core phenethylamine scaffold may yield compounds with improved selectivity for specific receptor subtypes, potentially leading to novel treatments for mood disorders or neurodegenerative diseases. However, further preclinical and clinical studies will be necessary to fully evaluate the safety and efficacy of these compounds.

In conclusion, recent research on 2-(2-Bromo-4,5-dimethoxyphenyl)propan-1-amine (CAS: 1781004-23-6) has advanced our understanding of its chemical properties, pharmacological effects, and potential applications. While challenges remain in fully characterizing its biological activity and therapeutic potential, the compound continues to serve as an important tool for studying neurotransmitter systems and developing novel psychoactive substances with potential medical benefits.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)